• About us
  • Core Technology
  • Bio-Service
  • Investors
  • Careers
中文 English
  • About us
    • Introduction
    • Information
      • Announcement
      • Events
    • Management Team
      • Members
      • Consultants
    • Contact us
  • Core Technology
    • New medicine development platform
      • Skin diseases
      • metabolic diseases
      • Anti-inflammation
      • Diseases related to deficient mitochondrion
      • Others
  • Bio-Service
    • Scientific products
      • Western Blot
      • Cell Culture Supplement
      • Protein Isolation
      • Protein Quantification
      • Dyes and Buffer
    • Supplier
      • Lumiprobe
      • Rigaku Reagents
    • Service
      • Quantitative MS and systematic biological analysis experiment service
      • Protein identity certification experiment service
      • Microarray and biological information analysis experiment service
  • Investors
  • Careers

About us

  • >
  • About us
  • >
  • Information
  • >
  • Announcement
  • Introduction
  • Information
    • Announcement
    • Events
    • Corporate image
  • Management
    • Members
    • Consultants
  • Contact us
2024-09-02
Australian Patent Granted for "METHODS FORTREATING DIABETIC ULCER" Following PCT National Phase Entry

Energenesis Biomedical Co., Ltd. has received approval from IP Australia for the patent application titled ”METHODS FOR TREATING DIABETIC ULCER”,Application No. 2022256582.

back
  • +886-2-26270835
  • +886-2-26270836
  • 6F.-3, No.21, Ln.583, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan (R.O.C.)
Copyright © 2017 ENERGENESIS BIOMEDICAL CO., LTD. All Rights Reserved. Design by choice